MARKET

RDY

RDY

Dr Reddys Labs
NYSE
80.37
+0.12
+0.15%
After Hours: 80.37 0 0.00% 17:33 09/13 EDT
OPEN
80.00
PREV CLOSE
80.25
HIGH
80.68
LOW
79.97
VOLUME
209.76K
TURNOVER
--
52 WEEK HIGH
84.46
52 WEEK LOW
63.35
MARKET CAP
13.39B
P/E (TTM)
20.12
1D
5D
1M
3M
1Y
5Y
1D
Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement
Benzinga · 19h ago
CITIUS PHARMACEUTICALS - DR. REDDY'S AGREED TO PARTIAL DEFERRAL WITHOUT PENALTY OF MILESTONE PAYMENT BY CITIUS ONCOLOGY INC
Reuters · 19h ago
CITIUS PHARMACEUTICALS INC - CO IS GUARANTOR OF OBLIGATIONS OF CITIUS ONCOLOGY, INC UNDER ASSET PURCHASE AGREEMENT
Reuters · 19h ago
Dr. Reddy’s Shareholders Approve Stock Split
TipRanks · 1d ago
Dr. Reddy’s Laboratories Addresses Allegations
TipRanks · 3d ago
Dr. Reddy's Issues Clarification Regarding Allegations Tied To Engagement With Agora Advisory; Confirms Engagement Of Dhaval Buch From October 2020 To April 2021, Prior To Madhabi Buch's SEBI Chairpersonship; Asserts Compliance With Laws And Denies Any Preferential Treatment By SEBI
Benzinga · 3d ago
Weekly Report: what happened at RDY last week (0902-0906)?
Weekly Report · 4d ago
Dr. Reddy’s API Facility Clears USFDA Inspection
TipRanks · 6d ago
More
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Webull offers Dr Reddy's Laboratories Ltd stock information, including NYSE: RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.